News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
824,896 Results
Type
Article (76082)
Company Profile (645)
Press Release (748167)
Multimedia
Podcasts (136)
Webinars (18)
Section
Business (228054)
Career Advice (3779)
Deals (39223)
Drug Delivery (129)
Drug Development (89388)
Employer Resources (198)
FDA (17909)
Job Trends (17142)
News (388412)
Policy (38863)
Tag
Academia (3001)
Academic (2)
Accelerated approval (9)
Adcomms (32)
Allergies (103)
Alliances (56278)
ALS (114)
Alzheimer's disease (1541)
Antibody-drug conjugate (ADC) (186)
Approvals (17859)
Artificial intelligence (353)
Autoimmune disease (34)
Automation (18)
Bankruptcy (403)
Best Places to Work (12632)
BIOSECURE Act (22)
Biosimilars (125)
Biotechnology (440)
Bladder cancer (95)
Brain cancer (38)
Breast cancer (376)
Cancer (2943)
Cardiovascular disease (237)
Career advice (3220)
Career pathing (34)
CAR-T (201)
CDC (38)
Cell therapy (548)
Cervical cancer (24)
Clinical research (72804)
Collaboration (1057)
Company closure (3)
Compensation (660)
Complete response letters (30)
COVID-19 (2893)
CRISPR (64)
C-suite (323)
Cystic fibrosis (117)
Data (2920)
Decentralized trials (2)
Denatured (47)
Depression (66)
Diabetes (366)
Diagnostics (6962)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (49)
Drug discovery (149)
Drug pricing (148)
Drug shortages (35)
Duchenne muscular dystrophy (126)
Earnings (94879)
Editorial (48)
Employer branding (25)
Employer resources (168)
Events (130325)
Executive appointments (895)
FDA (19538)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (959)
Gene editing (142)
Generative AI (32)
Gene therapy (418)
GLP-1 (912)
Government (5208)
Grass and pollen (6)
Guidances (180)
Healthcare (20900)
Huntington's disease (31)
IgA nephropathy (41)
Immunology and inflammation (171)
Immuno-oncology (8)
Indications (38)
Infectious disease (3073)
Inflammatory bowel disease (163)
Inflation Reduction Act (13)
Influenza (65)
Intellectual property (119)
Interviews (742)
IPO (17787)
IRA (55)
Job creations (4979)
Job search strategy (2627)
Kidney cancer (14)
Labor market (54)
Layoffs (580)
Leadership (25)
Legal (9938)
Liver cancer (84)
Lung cancer (418)
Lymphoma (206)
Machine learning (9)
Management (65)
Manufacturing (410)
MASH (92)
Medical device (14681)
Medtech (14686)
Mergers & acquisitions (22122)
Metabolic disorders (926)
Multiple sclerosis (103)
NASH (23)
Neurodegenerative disease (136)
Neuropsychiatric disorders (39)
Neuroscience (2258)
NextGen: Class of 2025 (7641)
Non-profit (5089)
Now hiring (48)
Obesity (477)
Opinion (287)
Ovarian cancer (98)
Pain (115)
Pancreatic cancer (116)
Parkinson's disease (193)
Partnered (23)
Patents (301)
Patient recruitment (148)
Peanut (54)
People (64472)
Pharmaceutical (132)
Pharmacy benefit managers (24)
Phase I (22495)
Phase II (31744)
Phase III (23934)
Pipeline (1616)
Policy (229)
Postmarket research (3280)
Preclinical (9991)
Press Release (72)
Prostate cancer (142)
Psychedelics (40)
Radiopharmaceuticals (276)
Rare diseases (500)
Real estate (7168)
Recruiting (75)
Regulatory (26324)
Reports (61)
Research institute (2659)
Resumes & cover letters (590)
Rett syndrome (9)
RNA editing (9)
RSV (54)
Schizophrenia (92)
Series A (165)
Series B (108)
Service/supplier (27)
Sickle cell disease (64)
Special edition (22)
Spinal muscular atrophy (166)
Sponsored (36)
Startups (4201)
State (2)
Stomach cancer (16)
Supply chain (81)
Tariffs (63)
The Weekly (87)
Vaccines (882)
Venture capital (54)
Weight loss (325)
Women's health (46)
Worklife (20)
Date
Today (142)
Last 7 days (526)
Last 30 days (2513)
Last 365 days (33711)
2025 (16746)
2024 (37917)
2023 (42567)
2022 (53927)
2021 (58722)
2020 (57665)
2019 (51316)
2018 (39098)
2017 (36856)
2016 (37798)
2015 (43821)
2014 (38560)
2013 (34695)
2012 (36547)
2011 (36602)
2010 (36146)
Location
Africa (1200)
Alabama (69)
Alaska (7)
Arizona (258)
Arkansas (14)
Asia (48849)
Australia (8388)
California (7539)
Canada (2317)
China (695)
Colorado (324)
Connecticut (339)
Delaware (194)
Europe (111208)
Florida (1112)
Georgia (258)
Hawaii (1)
Idaho (64)
Illinois (706)
India (31)
Indiana (381)
Iowa (18)
Japan (223)
Kansas (114)
Kentucky (32)
Louisiana (17)
Maine (73)
Maryland (1079)
Massachusetts (5761)
Michigan (270)
Minnesota (468)
Mississippi (3)
Missouri (96)
Montana (32)
Nebraska (26)
Nevada (79)
New Hampshire (73)
New Jersey (2110)
New Mexico (31)
New York (2119)
North Carolina (1211)
North Dakota (10)
Northern California (3250)
Ohio (244)
Oklahoma (16)
Oregon (46)
Pennsylvania (1617)
Puerto Rico (18)
Rhode Island (39)
South America (1572)
South Carolina (35)
South Dakota (1)
Southern California (2775)
Tennessee (124)
Texas (1128)
United States (28434)
Utah (224)
Virginia (200)
Washington D.C. (80)
Washington State (661)
West Virginia (4)
Wisconsin (81)
824,896 Results for "karl storz gmbh and co kg".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)
June 19, 2025
·
3 min read
Bio NC
Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KGKARL STORZ to provide up to $20 million in bridge financing
Asensus Surgical, Inc. announced that it has entered into a non-binding letter of intent with KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company to engage in diligence and negotiations regarding the terms of a potential transaction whereby KARL STORZ may acquire Asensus.
April 3, 2024
·
9 min read
Deals
Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ
Asensus Surgical, Inc. today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with KARL STORZ Endoscopy-America, Inc.
June 7, 2024
·
7 min read
Biotech Beach
KARL STORZ Launches CollaboratOR 3D for Apple Vision Pro
Pioneering MedTech company KARL STORZ is proud to announce the release of the CollaboratOR 3D app for Apple Vision Pro.
March 7, 2024
·
4 min read
Deals
KARL STORZ Acquires British AI Specialist Innersight Labs
The family-owned MedTech company KARL STORZ announces the acquisition of innovative software manufacturer Innersight Labs Ltd., headquartered in London.
January 10, 2024
·
4 min read
Press Releases
Asensus Surgical Announces Closing of Acquisition by KARL STORZ
August 23, 2024
·
4 min read
Business
KARL STORZ unifies its US organizations under a central management team, Sonal Matai named US President
KARL STORZ announced it will centralize management of its United States organizations, including its research and development, manufacturing, and commercial operations, to bring more innovative products to market worldwide with greater speed.
February 6, 2024
·
2 min read
Press Releases
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
August 15, 2024
·
3 min read
Deals
Luciole Medical AG Announces the Acquisition of Spiegelberg GmbH & Co. KG to Create a Leading Global Brain Monitoring Developer and Provider
Luciole Medical AG, a Swiss medical technology company specialized in brain monitoring, announced the acquisition of Spiegelberg GmbH & Co. KG, an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital.
June 27, 2023
·
4 min read
Press Releases
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
May 30, 2025
·
10 min read
1 of 82,490
Next
